Document:

Exhibit 10.4

 

VOTING AGREEMENT

 

This VOTING AGREEMENT
(this “Agreement”) is made and entered into as of January 26, 2021 (the “Effective Date”),
by and between Armata Pharmaceuticals Inc., a Washington corporation (the “Company”), Innoviva, Inc.,
a Delaware corporation (“Innoviva”) and Innoviva Strategic Opportunities LLC (a Delaware limited liability
company and wholly-owned subsidiary of Innoviva, “Strategic Opportunities” and together with Innoviva,
the “Stockholders”).

 

WITNESSETH:

 

WHEREAS, the
Company and Innoviva are parties to that certain Securities Purchase Agreement, dated January 27, 2020 (the “Purchase
Agreement”), pursuant to which, among other things, Innoviva acquired 8,710,800 shares of common stock (“Common
Stock”) of the Company (the “Purchased Shares”) and warrants to acquire additional 8,710,800
shares of Common Stock (the “Purchased Warrants”);

 

WHEREAS, in
connection with, and as a part of the transactions contemplated by, the Purchase Agreement, the Company and Innoviva entered into
that certain Investor Rights Agreement, dated February 12, 2020 (the “IRA”), pursuant to which,
among other things, Innoviva has certain rights with respect to the board of directors of the Company (the “Board”),
including the right to designate up to two (2) directors to the Board, subject to the terms and conditions set forth in the
IRA;

 

WHEREAS, the
Company and Stockholders intend to enter into a Securities Purchase Agreement, dated as of the date hereof, pursuant to which ,
among other things, Strategic Opportunities will acquire additional shares of Common Stock (such shares, the “Newly
Purchased Shares”) and additional warrants to purchase additional shares of Common Stock (such warrants, the “Newly
Purchased Warrants”), in each case, subject to the terms and conditions set forth in such agreement;

 

WHEREAS, Innoviva
may, in the future, transfer all or some of the Purchased Shares and/or Purchased Warrants to Strategic Opportunities; and

 

WHEREAS, the
parties hereto desire to enter into this Agreement to set forth certain rights and obligations of Stockholders with respect to
the Common Shares (as defined below).

 

NOW, THEREFORE,
in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below intending
to be legally bound, the parties hereto agree as follows:

 

1.            Certain
Definitions. For all purposes of and under this Agreement, the following terms shall have the following respective meanings:

 

“Applicable
Law” means with respect to any Person, any supranational, national, federal, state, provincial, local or other law,
constitution, treaty, convention, statute, ordinance, code, rule, regulation or common law or other similar requirement enacted,
adopted, promulgated or applied by any Governmental Authority, in each such case that is binding on or applicable to such Person,
or its subsidiaries or its or their respective properties, assets or businesses.

 

    

     

    

 

“Business
Day” means a day, other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required by Applicable Law to close.

 

“Common
Shares” means all shares of Common Stock beneficially owned by Stockholders as of the date hereof (including the
Purchased Shares and the Newly Purchased Shares) and as may be voluntarily acquired by Stockholders from time to time during the
period from the Effective Date through the Expiration Date (including by the exercise of the Purchased Warrants and the Newly Purchased
Warrants).

 

“Expiration
Date” means the earlier to occur of: (i) the second (2nd) anniversary of the Effective Date, and
(ii) approval by the U.S. Food and Drug Administration of any of the product candidates of the Company for marketing and commercial
distribution.

 

“Governmental
Authority” means any supranational, national, federal, state, provincial, local or other government, department,
authority, court, tribunal, commission, regulatory body or self-regulatory body (including any securities exchange), or any political
or other subdivision, department, agency or branch of any of the foregoing.

 

“Order”
means, with respect to any Person, any order, injunction, judgment, decision, determination, award, writ, ruling, stipulation,
assessment or decree or other similar requirement of, or entered, enacted, adopted, promulgated or applied by, with or under the
supervision of, a Governmental Authority or arbitrator, in each such case, that is binding upon or applicable to such Person or
its subsidiaries or its or their respective properties, assets or businesses.

 

“Person”
means any individual, general or limited partnership, corporation, limited liability company, business trust, joint stock company,
trust, unincorporated organization, joint venture, firm, association or other entity or organization (whether or not a legal entity),
including any Governmental Authority.

 

“Purchased
Securities” means the Purchased Shares, the Newly Purchased Shares, the Purchased Warrants and the Newly Purchased
Warrants.

 

“Proceeding”
means any suit (whether civil, criminal, administrative, judicial or investigative), claim, action, litigation, arbitration, mediation,
proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, audit, criminal prosecution,
in each case commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Authority
or any mediator, arbitrator or arbitration panel.

 

2.            Share
Voting Cap.

 

(a)            Following
the Effective Date, at every meeting of the stockholders of the Company, and at every adjournment or postponement thereof, and
on every action or approval by written consent of the stockholders of the Company in each case that are expressly for the purpose
of electing directors to the Board or removing directors from the Board (collectively, “Board Matters”),
the Stockholders (in their capacity as stockholders of the Company) shall not vote or take action by written consent any Common
Shares held by Stockholders collectively that exceed 49.5% of the total number of shares
of Common Stock issued and outstanding as of the record date for voting on the matters presented at such meeting or taking
action by written consent (the “Share Voting Cap”).

 

    2 

     

    

 

(b)            Following
the Effective Date, Common Shares held or otherwise beneficially owned by Stockholders in excess of the Share Voting Cap (“Excess
Shares”) shall be voted at every meeting of the stockholders of the Company, and at every adjournment or postponement
thereof, and on every action or approval by written consent of the stockholders of the Company, in each case solely with respect
to Board Matters, only if the Board authorizes Stockholders to vote such Excess Shares and such authorization is confirmed in writing
by the Company. If such authorization is given, and such confirmation is provided, the Stockholders shall be entitled to vote such
Excess Shares in their sole discretion.

 

(c)            For
the avoidance of doubt, nothing herein shall limit the Stockholders’ right to vote any Common Shares (including Excess Shares)
in any manner that Stockholders may determine in their sole discretion with respect to any matters submitted to the vote (or written
consent) of stockholders of the Company that are not Board Matters.

 

(d)            Stockholders
shall not enter into any agreement, arrangement or understanding with any Person to vote or give instructions in any manner inconsistent
with the terms of this Section 2.

 

(e)            In
the event of any issuance of shares of the Company’s voting securities hereafter to a Stockholder or a Stockholder’s
subsidiaries (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization,
or the like), in relation to such Stockholder’s Common Shares, such additional shares shall automatically become subject
to this Agreement and such Stockholder shall cause such subsidiary transferee to become a party to this Agreement by executing
a joinder hereto.

 

3.            Representations
and Warranties of Stockholder. Stockholders hereby represent and warrant to the Company as follows:

 

(a)            Ownership.
Stockholders (i) are the beneficial owner of the Purchased Securities and will be the beneficial owner of any other Common
Shares they may acquire; (ii) do not own as of the date hereof, of record or beneficially, any shares of capital stock of
the Company (or rights to acquire any such shares) other than the Purchased Securities; and (iii) have the sole right to vote,
dispose of and exercise and holds sole power to issue instructions with respect to the matters set forth in Section 2
hereof and sole power to agree to all of the matters set forth in this Agreement with respect to all of its Common Shares, subject
to the terms of this Agreement.

 

(b)            Power;
Binding Agreement. Stockholders have legal capacity and all requisite power and authority to execute and deliver this Agreement
and to perform their obligations hereunder. This Agreement has been duly and validly executed and delivered by Stockholders, and,
assuming this Agreement constitutes a valid and binding obligation of the Company, constitutes a valid and binding obligation of
Stockholders, enforceable against Stockholders in accordance with its terms, except that such enforceability may be limited by
applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Applicable Laws affecting
or relating to creditors’ rights generally and is subject to general principles of equity (regardless of whether such enforceability
is considered in a proceeding in equity or law).

 

    3 

     

    

 

(c)            No
Conflicts. The execution and delivery by Stockholders of this Agreement and the performance by Stockholders of its obligations
hereunder will not: (i) result in a violation or breach of, or constitute (with or without notice or lapse of time or both)
a default under, or conflict with any agreement to which either Stockholder is a party or by which the Purchased Shares are bound,
or (ii) violate, or require any consent, approval, or notice under, any provision of any judgment, Order or decree or any
Applicable Law that is applicable to either Stockholder or any of the Purchased Shares (other than filings required pursuant to
securities laws), except, in the case of (i) or (ii) above, as would not reasonably be expected, either individually
or in the aggregate, to impair the ability of Stockholders to perform their obligations hereunder on a timely basis.

 

4.            Representations
and Warranties of the Company. The Company hereby represents and warrants to Stockholders as follows:

 

(a)            Power;
Binding Agreement. The Company has the legal capacity and all requisite power and authority to execute and deliver this Agreement,
to perform its obligations hereunder. This Agreement has been duly authorized, executed and delivered by the Company, and, assuming
this Agreement constitutes a valid and binding obligation of Stockholders, constitutes a valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except that such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other similar Applicable Laws affecting or relating to creditors’ rights generally
and is subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity
or law).

 

(b)            No
Conflicts. The execution, delivery, and performance of this Agreement by the Company will not (i) result in a violation
or breach of, or constitute (with or without notice or lapse of time or both) a default under, or conflict with (A) any provisions
of the certificate of incorporation or bylaws of the Company, (B) any contract to which the Company is a party or by which
the Company’s assets or securities may be bound, or (ii) violate, or require any consent, approval, or notice under,
any provision of any Order or any Applicable Law that is applicable to the Company or its assets or securities, except, in the
case of (i) or (ii) above, as would not reasonably be expected, either individually or in the aggregate, to impair the
ability of the Company to perform its obligations hereunder on a timely basis.

 

5.            Further
Assurances. Subject to the terms and conditions of this Agreement, each party hereto shall execute and deliver any additional
documents and instruments and take, or cause to be taken, all actions, and do, or cause to be done, all things as may reasonably
be deemed by the other party to be necessary or desirable to fulfill the intended purpose of this Agreement.

 

    4 

     

    

 

6.            Effectiveness
and Termination.

 

(a)            Effectiveness.
This Agreement shall become effective on the Effective Date.

 

(b)            Termination.
This Agreement, and all rights and obligations of the parties hereunder, shall terminate and shall have no further force or effect
as of the Expiration Date.

 

(c)            Survival.
Notwithstanding the foregoing, nothing set forth in this Section 6 or elsewhere in this Agreement shall relieve any
party hereto from liability, or otherwise limit the liability of any party hereto, for any material breach of this Agreement prior
to such termination. This Section 6 and Sections 1 and 7 (as applicable) shall survive any termination
of this Agreement.

 

7.            Miscellaneous.

 

(a)            Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental
Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement
shall remain in full force and effect and shall in no way be affected, impaired or invalidated. Upon such a determination, the
parties hereto agree to negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner, in order that substance of this Agreement be consummated as originally contemplated
to the fullest extent possible.

 

(b)            Binding
Effect and Assignment. Neither this Agreement nor any of the rights, interests or obligations of Stockholders hereunder may
be assigned by Stockholders (whether by operation of law or otherwise) without prior written consent of the Company. Notwithstanding
the foregoing, either Stockholder may assign this Agreement and its rights, interests or obligations hereunder to an affiliate
of such Stockholder without the consent of the Company. This Agreement and all of the provisions hereof shall be binding upon,
inure to the benefit of and be enforceable by, the parties and their respective successors and permitted assigns and the provisions
of this Agreement are not intended to confer upon any Person other than the parties hereto any rights or remedies hereunder.

 

(c)            Amendments.
This Agreement may be amended by the parties hereto only by an instrument in writing signed on behalf of each of the parties hereto.

 

(d)            Specific
Performance; Injunctive Relief. The parties hereto acknowledge that they will be irreparably harmed and that there shall be
no adequate remedy at law for a violation of any of the covenants or agreements set forth herein. Therefore, it is agreed that,
in addition to any other remedies that may be available to the non-breaching party at law, the non-breaching party shall have the
right to enforce such covenants and agreements by specific performance, injunctive relief or by any other means available to it
in equity, without the requirement of posting a bond or other security.

 

    5 

     

    

 

(e)            Notices.
Any notices or other communications required or permitted under, or otherwise given in connection with, this Agreement shall be
in writing and shall be deemed to have been duly given (i) when delivered or sent if delivered in person, (ii) on the
Business Day after dispatch by registered or certified mail (return receipt requested), (iii) on the next Business Day if
transmitted by an express courier (with confirmation), or (iv) on the date delivered if sent by email (provided confirmation
of email receipt is obtained), in each case as follows:

 

If to the Company,
to:

 

Armata Pharmaceuticals, Inc.

4503 Glencoe Avenue

Marina del Rey, CA

Attention: Chief Executive Officer

Email: info@armatapharma.com

 

with a copy (which shall not constitute
notice) to:

 

Thompson Hine LLP

335 Madison Avenue

12th Floor

New York, New York 10017-4611

Attention: Faith L. Charles

Email: faith.charles@thompsonhine.com

 

If to Stockholder,
to:

 

c/o Innoviva, Inc.

1350 Old Bayshore Highway Suite 400

Burlingame, CA 94010

Attention: Chief Executive Officer

Email: pavel.raifeld@inva.com

 

with a copy (which shall not constitute
notice) to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

Attention: Jared Fertman

Email: jfertman@willkie.com

 

(f)             No
Waiver. The failure of any party hereto to exercise any right, power or remedy provided under this Agreement or otherwise available
in respect of this Agreement at law or in equity, or to insist upon compliance by any other party with its obligation under this
Agreement, and any custom or practice of the parties at variance with the terms of this Agreement, shall not constitute a waiver
by such party of such party’s right to exercise any such or other right, power or remedy or to demand such compliance.

 

    6 

     

    

 

(g)            Governing
Law. This Agreement and any Proceedings arising out of or related hereto or to the inducement of any party hereto to enter
into this Agreement (whether for breach of contract, tortious conduct or otherwise and whether predicated on common law, statute
or otherwise) shall be governed by and construed in accordance with the laws of the State of Delaware, including all matters of
construction, validity, and performance, without regard to the conflicts of law rules of such State that would refer a matter
to the laws of another jurisdiction.

 

(h)            Consent
to Jurisdiction. The parties hereto agree that any Proceeding seeking to enforce any provision of, or based on any matter arising
out of or in connection with, this Agreement shall be brought in the Chancery Court of the State of Delaware located in Wilmington,
Delaware and any state appellate court therefrom located in Wilmington, Delaware, or, if no such state court has proper jurisdiction,
the Federal District Court for the District of Delaware located in Wilmington, Delaware, and any appellate court therefrom. Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of such court in respect of any legal or equitable Proceeding
arising out of or relating to this Agreement, or relating to enforcement of any of the terms of this Agreement, and hereby waives,
and agrees not to assert, as a defense in any such Proceeding, any claim that it is not subject personally to the jurisdiction
of such court, that the Proceeding is brought in an inconvenient forum, that the venue of the Proceeding is improper or that this
Agreement may not be enforced in or by such courts. Each Party agrees that notice or the service of process in any Proceeding arising
out of or relating to this Agreement shall be properly served or delivered if delivered in the manner contemplated by Section 7(e) or
in any other manner permitted by Applicable Law.

 

(i)             Waiver
of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING ARISING
OUT OF OR RELATED TO THIS AGREEMENT CONTEMPLATED HEREBY.

 

(j)             Rules of
Construction. Each of the parties hereto acknowledge that it has been represented by counsel of its choice throughout all negotiations
that have preceded the execution of this Agreement. Consequently, in the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

(k)            Entire
Agreement. This Agreement (together with any other documents and instruments referred to herein) constitutes the entire agreement,
and supersedes all other prior agreements and understandings, both written and oral, among the parties and their affiliates, or
any of them, with respect to the subject matter hereof.

 

(l)             Interpretation.

 

 (i)            Whenever
the words “include,” “includes” or “including” are used in this Agreement they shall be deemed
to be followed by the words “without limitation.”

 

    7 

     

    

 

 (ii)           The
article and section headings contained in this Agreement are for reference purposes only and shall not in any way affect or be
deemed to affect the meaning or interpretation of this Agreement.

 

 (iii)          Words
describing the singular number shall be deemed to include the plural and vice versa, and words denoting any gender shall be deemed
to include all genders.

 

(m)           Expenses.
Except as expressly provided for herein, all fees, costs and expenses incurred in connection with this Agreement shall be paid
by the party incurring such fees, costs and expenses.

 

(n)            Non-Recourse.
This Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement
may only be brought against the Persons that are expressly named as parties hereto and then only with respect to the specific obligations
set forth herein with respect to such party.

 

(o)            Counterparts;
Facsimile Transmission of Signatures. This Agreement may be signed in any number of counterparts, each of which shall be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Signatures to this Agreement
transmitted by facsimile transmission, by electronic mail in PDF form, or by any other electronic means designed to preserve the
original graphic and pictorial appearance of a document, will be deemed to have the same effect as physical delivery of the paper
document bearing the original signatures.

 

[Remainder of Page Intentionally
Left Blank]

 

    8 

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed on the date first above written.

 

	 	 	COMPANY:
	 	 	 
	 	 	Armata Pharmaceuticals Inc.
	 	 	 
	 	 	 
	 	 	By:	                           
	 	 	 	Name:
	 	 	 	Title:

 

    

     

    

 

	 	 	STOCKHOLDERS:
	 	 	 
	 	 	INNOVIVA, INC.
	 	 	 
	 	 	 
	 	 	By:	                     
	 	 	 	Name: Pavel Raifeld
	 	 	 	Title: Chief Executive Officer
	 	 	 
	 	 	 
	 	 	INNOVIVA STRATEGIC OPPORTUNITIES LLC
	 	 	 
	 	 	BY: Innoviva, Inc. (its managing member)
	 	 	 
	 	 	 
	 	 	By:	 
	 	 	 	Name: Pavel Raifeld
	 	 	 	Title: Chief Executive OfficerDocument

Ex. 10.1

AMENDED CONTRACT OF EMPLOYMENT 

Statement of Main Terms and Conditions of Employment, pursuant to the
Employment Rights Act 1996

PARTIES TO THE CONTRACT OF EMPLOYMENT
Employer:     Hologic Limited, Heron House, Oaks Business Park, Crewe Road, Wythenshawe, Manchester M23 9HZ. Hereinafter called “the Company”

Employee:     Jan Verstreken

JOB TITLE
You will be employed as Group President, International. You may be asked to perform additional duties or other roles from time to time during your employment with the Company.

PLACE OF WORK
(a)You may be required to travel and work on behalf of the Company within the United Kingdom and globally for the proper discharge of your duties. You will be entitled to reimbursement of such expenses as detailed in the company’s Expense Claim procedure.

RELEVANT DATES
(a)For continuous service purposes, your start date with the company will continue as 3rd January 2017

REMUNERATION    
(a)Your remuneration is at the basic rate of £425,600 per annum.
(b)You are eligible to participate in the Company’s Short-term Incentive Plan (STIP) with annual target of 75% base pay, subject to the rules that are from time to time in place alongside objectives set.
(c)You will be paid monthly into a personal bank account or building society account by credit transfer on or about the 20th day of the month in which salary is earned.
(d)Salaries are normally reviewed annually in October. Reviews are at the total discretion of the Directors.  Increases are not automatic and take into account a number of variables, including performance, market value, qualifications and future potential.
(e)In accordance with the Employment Rights Act 1996 you hereby consent to the deduction of any sum owing by you to the Company from your salary or any other payment or payments due from the Company to you hereunder or otherwise. You also agree to make any payment of sums owing by you to the Company as requested. Such payments are likely to arise from but are not limited to remuneration/expenses under/overpayments etc.

HOUSING SUPPORT
(a)You will be entitled to receive a monthly payment of £2,193.00 for housing support.

HOURS OF WORK
(a) Your normal hours of work will be 37.5 hours per week (Monday to Friday), which may vary according to the requirements of the business due to changing economic conditions and any     future reorganization of the business. 
(b) The Company allows for each member of staff to take unpaid break(s) totaling one hour each     day normally between 12.00 noon and 2.00pm.

Please note that these hours fall well below the maximum hours allowed under the Working Time Regulations 1998.                           

(c ) The employee acknowledges that the limit under Regulation 4 (1) of the Working Time     Regulations 1998 shall not apply to him/her and accordingly agrees to work longer than 48 hours 

a week on average whenever necessary for the proper discharge of his/her duties, or in any event as may be required by the company.  The employee is entitled to withdraw such agreement by providing three months’ notice in writing to their manager.  

Please note that "working time" for the purposes of the Working Time Regulations 1998 is defined as time at which you are at the Company's disposal, ready and willing to perform your duties.

COMPANY CAR / CAR ALLOWANCE
You will receive a car or car allowance as part of your compensation package, with a monthly value £1,315.00

GLOBAL HEALTH PLAN / ALLOWANCE
You will receive access to a Global Health Plan or receive a Global Health Plan allowance as part of your compensation package, with a monthly value of £1,096.00

HOLIDAYS
(a)Your annual paid holiday entitlement is 25 days plus English statutory public holidays. Holiday requests should be made to your manager as far in advance as is practical. Managers will make every effort to accommodate leave requests, but may not be able to approve all requests based on business need. You therefore should not make any financial commitments to a holiday before receiving approval.  
 (d) The Company’s Holiday Year runs from January to December and employees should make every effort to ensure that holidays are taken within that period. Outstanding holidays may not be carried over without prior authorisation from your manager.  If granted, carried-over days they must be taken during the first quarter of the following calendar year.
(e) In some locations it may be the company practice to close for one week at Christmas.  If this is the case, you will be required to allocate part of your annual holiday entitlement to facilitate this. Christmas or other arrangements will be notified to you in advance.
(b)Holiday pay may also be withheld in whole or in part should you fail to give proper notice of termination of your employment or should you leave prior to the end of your notice period. In such a case your holiday pay will be reduced by the number of days’ notice not worked. Any overtaken pro-rata holiday entitlement will be deducted from your final salary.

PENSION ARRANGEMENTS
The Company grants access to its Group Pension Scheme, or will make an equivalent allowance for payment into your personal pension vehicle.

LIFE ASSURANCE
The Company provides Life Assurance Cover for all permanent employees at the rate of 2 years gross remuneration.  You will be eligible for this benefit from your first day of employment.  Further details are available in the Employee Handbook.

INCOME PROTECTION
You will automatically be enrolled on the Company’s UK Income Protection scheme, subject to the rules of that scheme.

SICK PAY/COMPANY SICK PAY ENTITLEMENT
(a)You will be entitled to Company Sick Pay providing you comply with the Company Sick Pay procedures as detailed in the Employee Handbook.
(b)Sickness absence is calculated on a rolling 12 month basis and details of entitlements are available in the Employee Handbook.
(c)In accordance with legislation, the Company reserves the right to withhold company and/or statutory sick pay in exceptional circumstances. 
(d)You are required to notify the Company of any absence caused by the negligence of a third party.  Full details of the circumstances and particulars of any claims/settlements awarded
Jan Verstreken
December 11, 2020
2 of 5 Pages

must be provided by you.  The Company reserves the right to request a refund of some or all of the sick payments paid to you.

MEDICAL REPORTS
The Company reserves the right to require employees to undergo medical examinations/reports in respect of either sickness/absence (regardless of duration) or in respect of the Access to Medical Reports Act 1988 or otherwise. Costs will be borne by the company and by signing this agreement you acknowledge that you have given your consent to the aforesaid.
CHANGE TO PERSONAL CIRCUMSTANCES
You are required to notify your Manager in writing of any change of address or personal circumstances (including health conditions) as soon as is practicable.

DISCIPLINARY PROCEDURE
Details of the Company Disciplinary Procedure are available from your Manager or can be found in the Employee Handbook. Please note that this procedure is non-contractual and does not form part of your contract of employment.

GRIEVANCE PROCEDURE
You have a right to express a grievance relating to your employment which in the first instance should be raised informally with your Manager who will make every effort to resolve the issue as soon as possible.  Please refer to the Employee Handbook for further information.

 WHOLE TIME AND ATTENTION
(a) During your employment you shall be obliged to faithfully and diligently carry out the careful instructions of the Company and at all times use your best endeavours to promote the best interests of the Company.
(e)You may not work in a self-employed capacity or for anyone other than the Company without the prior written express permission of your manager. 
(f)You are not permitted to sell or attempt to sell goods or services for personal gain from or on the premises of the Company without prior express permission from your Manager.

CONFIDENTIALITY 
(a)You shall not make use of, divulge or communicate to any person (save in the proper performance of your duties under this contract) any of the trade secrets or other confidential information of or relating to the Company or any Group Company, which you may have received or obtained while in the service of the Company or any Group Company.
(b)This restriction shall continue to apply after the termination of your employment without limit in point of time but shall cease to apply to information ordered to be disclosed by a Court of competent jurisdiction or otherwise required to be disclosed by law.
(c)For the purposes of this contract confidential information shall include, but shall not be limited to the secrets, dealings, details of customers, suppliers or employees and any details relating to the marketing or pricing of products or financial information of any kind.

DATA PROTECTION
(a)The Company retains and processes personal data concerning employees for the purpose of efficient human resource management.  You agree to the Company doing so and acknowledge that such data may be disclosed to employees and the Company’s professional advisors, in accordance with the principles of the Data Protection Act 1998. 
(b)The Company has established proper safeguards to prevent misuse of such data and takes all reasonable steps to ensure that data is accurate, complete, current and relevant.  If you consider your data may be inaccurate or if you simply wish to have access to it to satisfy yourself, you may do so by contacting your Manager.

Jan Verstreken
December 11, 2020
3 of 5 Pages

DATA SECURITY
(a)You must not at any time remove any documents or tangible items from the Company’s premises which belong to the Company or which contain any confidential information without the prior written consent of your Manager.
(b)You must not use computer hardware/software without proper authorisation or licence   (including the copying of software outside the terms of the licence). You must not use your own hardware and/or software on Company business, whether on Company premises or not, unless approval has been given in writing by your Manager. If such permission is given, the ownership of all Company data remains with the Company for all time and must not be divulged to any unauthorised person either during or after your employment with the Company.
(c)You must return to the Company upon request and, in any event, upon the termination of your employment, all documents and computer files and discs, and tangible items which belong to the Company or which contain or refer to any confidential information which are in the your possession or under your control. 
(d)   You must, if requested by the Company, delete all confidential information from any reusable material and destroy all other documents and tangible items which contain or refer to any confidential information and which are in your possession or under your control.

TERMINATION OF EMPLOYMENT
(a)In the event of resignation, you are required to give the Company 3 months of notice of your intention to resign. The right to waive all or part of the notice period may be exercised by either party by mutual consent.
(b)In the event that your employment is terminated by the Company for any reason other than change in control (i.e., the Company being acquired), you will receive 24 months of total compensation including base pay, bonus, allowances and benefits (or cash equivalent). In the event your employment is terminated by the Company for change in control, you will receive   accrued obligations (includes pro-rated bonus), 2.99x annual base salary, 2.99x bonus and full vesting of equity.  The change in control period extends for 3 years after the change in control occurs.  Any payments under this provision are subject to local taxes and deductions.

NON-COMPETITION & NON-SOLICITATION
(a)In the event of termination via resignation or termination for any reason (including change in control), you are expressly prevented from soliciting employees who currently work for the Company, or who did so in the 12 months prior to leaving.
(b)In the event of termination via resignation or termination for any reason (including change in control), you expressly refrain from entering the service of a company manufacturing or selling products or services likely to compete with those of the Company, to create on its own account a similar company or to participate directly or indirectly, in any capacity whatsoever. As such, you are prohibited from prospecting, for any product or service likely to compete with the products or services of the Company, the customers of the Company and to deal with any natural or legal person who has been the client of the Company at any time during the two (2) years preceding his effective departure from the Company. The territory concerned by this non-compete obligation is the United Kingdom.
Furthermore it is expressly agreed that the execution of this clause is limited to a period of twelve (12) months from the date of the effective departure from the Company. During this non-compete period, the Company will pay an indemnity equal to the remuneration received by the employee on the basis of the previous 12 months, representing full compensation for the wages, bonuses and benefits received by the employee.

It is understood that in all circumstances the Company will be able either to reduce the duration of the period of application of the non-competition clause, or to give up the latter.

Jan Verstreken
December 11, 2020
4 of 5 Pages

INVENTIONS AND OTHER INDUSTRIAL AND/OR INTELLECTUAL PROPERTY
(a)The parties foresee that you may create intellectual property in the course of your duties hereunder and agree that in this respect you have a special responsibility to further the interests of the Company. 
(b)Any Intellectual Property created by you during the continuance of your employment whether normal working hours or otherwise hereunder (whether capable of being patented or registered or not made or discovered in the course of your employment hereunder) and whether using the Company’s offices and facilities or otherwise in conjunction with or in any way affecting or relating to the business of any Company in the Group or capable of being used or adapted for use therein or in connection therewith shall forthwith be disclosed to the Company and shall (subject to sections 39 to 43 Patents Act 1977) belong to and be the absolute property of the Company.

HEALTH AND SAFETY
(a)    Whilst employed by the Company you must take care for your own health and safety and     that of fellow employees or other people who may be affected by your actions at work. You are expected to co-operate with management and/or other employees in observing statutory duties as well as company policies relating to health and safety, as defined in the company's Health and Safety Policy.

(b)  You must advise your Manager as soon as possible if you believe the design of your workplace is adversely affecting your health, or if you experience problems, headaches, eyestrain or muscular aches or pains, which you believe, may be attributable to your working conditions. 

VARIATION
You will be notified in writing of any variations to your Particulars of Employment in so far as those variations are not significant. You will be consulted prior to the introduction of significant variations.

Copies of documents referred to in this Statement are available from your Manager.
You should regularly read the notice board in your workplace to ensure that you are aware of changes regarding your employment with the Company.

Jan Verstreken
December 11, 2020
5 of 5 Pages

			
	
	This agreement contains the written particulars of employment required to be given to you pursuant to the Employment Rights Act 1996 and the Working Time Regulations 1998 (as amended from time to time). For these statutory purposes it is confirmed that it is correct as at the date shown.
	
	
	EMPLOYEE:
	I have received a copy of these Particulars of Employment as required by S1. ERA 1996 and the attached documents, all of which I have read, understood and agree to be bound by the rules contained within them.
	
	Signed:     

	By: /s/ Jan Verstreken
	Name: Jan Verstreken
	
	EMPLOYER: 

	Signed on behalf of the Company :  
/s/ Carmel O’Kane

	Name: Carmel O'Kane
VP Human Resources EMEAC                

	Date: December 11, 2020
	

        
Jan Verstreken
December 11, 2020
6 of 5 Pages

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]